Data coverage, completeness and provenance for IMUGENE LIMITED in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T05:10:11. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.0350 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.0380 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.0350 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.0360 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.0350 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/IMU/prices · Price parameters and adjustment semantics
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Employees: 14 · Website: https://imugene.com · Profile fields populated: 75%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/IMU/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 26 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 26 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 26 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 25 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 27 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/IMU
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/IMU/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/IMU/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/IMU/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/IMU/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/IMU
Free tier — instant API key. Built for AI agents.